Senolytic Therapies UNITY Biotechnology is developing senolytic therapies to clear senescent cells in retinal diseases, presenting an opportunity to target ophthalmology market with innovative treatments.
Strategic Event Participation With participation in events like ARVO 2025 Annual Meeting, UNITY Biotechnology is actively engaging with key industry stakeholders, providing a platform for networking and potential collaborations.
Key Personnel Additions Recent appointments of experienced professionals like Yehia Hashad and Federico Grossi in leadership roles strengthen the company's expertise and credibility, offering avenues for strategic partnerships and business growth.
Research Publications Publication of research in reputable journals like Nature Medicine showcases UNITY Biotechnology's scientific advancements, enhancing its reputation and attracting interest from potential investors or collaborators.
Market Expansion & Differentiation UNITY's focus on retinal diseases and ongoing clinical studies like the ENVISION trial for wet AMD patients differentiate it in the biotechnology sector, opening doors for partnerships with healthcare providers seeking innovative solutions.
$10M$50M
$100M$1B
$50M$100M
$10M
$10MUNITY Biotechnology uses 8 technology products and services including cdnjs, MySQL, Module Federation, and more. Explore UNITY Biotechnology's tech stack below.
| UNITY Biotechnology Email Formats | Percentage |
| First.Last@unitybiotechnology.com | 96% |
| FirstLast@unitybiotechnology.com | 2% |
| First.Middle@unitybiotechnology.com | 1% |
| FLast@unitybiotechnology.com | 1% |
Biotechnology ResearchUnited States51-200 Employees
UNITY is harnessing pathways of aging biology to develop new medicines, with a focus on retinal diseases. As pioneers in cellular senescence, UNITY is advancing the first senolytic therapeutic candidate for retinal diseases that aims to restore diseased tissue to a healthier state, a potentially paradigm shifting treatment in ophthalmology.
Company Overview
Media & News
Funding & FinancialsUNITY Biotechnology has raised a total of $4.3M of funding over 8 rounds. Their latest funding round was raised on Nov 10, 2023 in the amount of $4.3M.
UNITY Biotechnology's revenue is in the range of $10M$50M
Funding & FinancialsUNITY Biotechnology has raised a total of $4.3M of funding over 8 rounds. Their latest funding round was raised on Nov 10, 2023 in the amount of $4.3M.
UNITY Biotechnology's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com